- Home
- MRSN
as 02-21-2025 4:00pm EST
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 71.9M | IPO Year: | 2017 |
| Target Price: | $6.00 | AVG Volume (30 days): | 5.4M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.49 - $6.28 | Next Earning Date: | 03-07-2025 |
| Revenue: | $34,837,000 | Revenue Growth: | -14.70% |
| Revenue Growth (this year): | -12.27% | Revenue Growth (next year): | -12.33% |
Stock Insider Trading Activity of Mersana Therapeutics Inc. (MRSN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Protopapas Anna | MRSN | Director | Jan 15 '25 | Sell | $0.58 | 8,637 | $5,009.46 | 168,041 | |
| Lowinger Timothy B | MRSN | SVP, Chief Sci.&Tech. Officer | Jan 15 '25 | Sell | $0.58 | 8,048 | $4,667.84 | 257,673 | |
| Bala Mohan | MRSN | SVP, Chief Development Officer | Jan 15 '25 | Sell | $0.58 | 5,939 | $3,444.62 | 68,872 | |
| Mandelia Ashish | MRSN | VP, Chief Accounting Officer | Jan 15 '25 | Sell | $0.58 | 3,554 | $2,061.32 | 57,519 | |
| Huber Martin H. Jr. | MRSN | President, CEO | Jan 15 '25 | Sell | $0.58 | 4,514 | $2,618.12 | 122,875 | |
| Carvajal Alejandra | MRSN | SVP, Chief Legal Officer | Jan 15 '25 | Sell | $0.58 | 5,096 | $2,955.68 | 78,296 | |
| DeSchuytner Brian | MRSN | SVP, COO & CFO | Jan 15 '25 | Sell | $0.58 | 8,470 | $4,912.60 | 121,393 | |
| Protopapas Anna | MRSN | Director | Jan 14 '25 | Sell | $0.63 | 6,191 | $3,900.33 | 168,041 | |
| Lowinger Timothy B | MRSN | SVP, Chief Sci.&Tech. Officer | Jan 14 '25 | Sell | $0.63 | 1,794 | $1,130.22 | 257,673 | |
| Mandelia Ashish | MRSN | VP, Chief Accounting Officer | Jan 14 '25 | Sell | $0.63 | 1,791 | $1,128.33 | 57,519 |
Latest Mersana Therapeutics Inc. News
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
16 days ago
William Blair Initiates Coverage on Mersana Therapeutics With Outperform Rating
GlobeNewswire
23 days ago
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
MT Newswires
a month ago
Wedbush Cuts Price Target on Mersana Therapeutics to $4 From $7, Keeps Outperform Rating
Benzinga
a month ago
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
MT Newswires
a month ago
Mersana Therapeutics' XMT-1660 Gains Additional US FDA Fast Track Designation
MT Newswires
a month ago
Mersana Therapeutics Says Initial Data From Cancer Drug Trial Shows Promise, Shares Rise Premarket
GlobeNewswire
a month ago
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Compare MRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRSN Mersana Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.